Stockreport

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

AVROBIO, Inc.  (AVRO) 
Last avrobio, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.avrobio.com/investor-relations
PDF No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trialPost- [Read more]